The goal of designing and synthesizing peptides based on Glu-Ureido was to produce peptides that would specifically accumulate in prostate tumor lesions, have a high binding affinity to PSMA-positive cells, and be stable in biological conditions [47]. This evidence concerns the gene FOLH1 and prostate neoplasm.